denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, MDS, adult, CHIP, elderly, Chronic Myeloid Malignancies, CMML, Diseases, Therapies, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Study Population, Human
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, MDS, adult, CHIP, elderly, Chronic Myeloid Malignancies, CMML, Diseases, Therapies, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Study Population, Human
Sunday, December 10, 2023: 4:30 PM-5:30 PM
Halls G-H - Blood Journals Studio
(San Diego Convention Center)
Clonal hematopoiesis (CH) is a common, ageing-associated condition caused by acquired genetic changes in hematopoietic stem and precursor cells. While CH often is a benign condition, it can progress to an overt myeloid, or less frequently lymphoid, malignancy in a minority of affected individuals. The last years have seen great advances in our understanding of genetic and clinical factors, and the underlying mechanisms, that associate with progression of clonal hematopoiesis to hematologic neoplasia. Predictive models that allow identification of individuals at high risk of progression also open the way for pre-emptive therapeutic approaches aimed at averting progression.
In line with the ASH Agenda for Hematology Research that identifies Genetics and Genomics, as well as Hematology Across the Age Continuum as key research priorities, this poster walk will focus on “Progression of Clonal Hematopoiesis to Hematologic Neoplasms”. It will highlight some of the most exciting new insights into topics including the genetics of high-risk CH, biology of CH-to-neoplasia progression, clinical risk prediction models, and innovative therapeutic approaches aimed at treating pre-neoplastic CH.
See more of: ASH Poster Walks